JP2013528394A - Ｍｌｋ４遺伝子、新規の癌診断および予後マーカー - Google Patents

Ｍｌｋ４遺伝子、新規の癌診断および予後マーカー Download PDF

Info

Publication number
JP2013528394A
JP2013528394A JP2013514792A JP2013514792A JP2013528394A JP 2013528394 A JP2013528394 A JP 2013528394A JP 2013514792 A JP2013514792 A JP 2013514792A JP 2013514792 A JP2013514792 A JP 2013514792A JP 2013528394 A JP2013528394 A JP 2013528394A
Authority
JP
Japan
Prior art keywords
mlk4
cells
gene
diagnostic method
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013514792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528394A5 (https=
Inventor
アルベルト・バルデッリ
ミリアム・マルティニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2013528394A publication Critical patent/JP2013528394A/ja
Publication of JP2013528394A5 publication Critical patent/JP2013528394A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2013514792A 2010-06-15 2010-06-15 Ｍｌｋ４遺伝子、新規の癌診断および予後マーカー Pending JP2013528394A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2010/052684 WO2011158061A1 (en) 2010-06-15 2010-06-15 Mlk4 gene, a new diagnostic and prognostic marker in cancers

Publications (2)

Publication Number Publication Date
JP2013528394A true JP2013528394A (ja) 2013-07-11
JP2013528394A5 JP2013528394A5 (https=) 2013-08-22

Family

ID=43086697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013514792A Pending JP2013528394A (ja) 2010-06-15 2010-06-15 Ｍｌｋ４遺伝子、新規の癌診断および予後マーカー

Country Status (6)

Country Link
US (1) US9127319B2 (https=)
EP (1) EP2582837A1 (https=)
JP (1) JP2013528394A (https=)
AU (1) AU2010355523B2 (https=)
CA (1) CA2804335A1 (https=)
WO (1) WO2011158061A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
CN113201073A (zh) * 2012-11-21 2021-08-03 詹森生物科技公司 双特异性EGFR/c-Met抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082458A2 (en) * 2003-02-21 2004-09-30 The Johns Hopkins University Tyrosine kinome
WO2005095631A2 (en) * 2004-03-02 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 alpha (mlk4 alpha)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861239B1 (en) * 1999-09-20 2005-03-01 New York University Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof
WO2005095637A1 (en) * 2004-03-02 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 beta (mlk4 beta)
ES2426814T3 (es) 2007-03-13 2013-10-25 Amgen Inc. Mutaciones de K-ras y B-raf y terapia con anticuerpos anti-EGFr

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082458A2 (en) * 2003-02-21 2004-09-30 The Johns Hopkins University Tyrosine kinome
WO2005095631A2 (en) * 2004-03-02 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 alpha (mlk4 alpha)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6014042799; ＭＡＲＴＩＮＩ　Ｍ．　ｅｔ　ａｌ: 'ＭＬＫ４，　ａ　ｎｏｖｅｌ　ｏｎｃｏｇｅｎｉｃ　ｋｉｎａｓｅ　ｉｎ　ｔｈｅ　ＲＡＳ　ｐａｔｈｗａｙ' ＳＩＢＢＭ　Ｓｅｍｉｎａｒ"Ｆｒｏｎｔｉｅｒｓ　ｉｎ　Ｍｏｌｅｃｕｌａｒ　Ｂｉｏｌｏｇｙ"Ｐａｄｕａ　３-５　Ｊｕｎｅ　２０１０ , 20100605, ＳＩＢＢＭ　Ｓｅｍｉｎａｒ *
JPN6014042801; ＢＡＲＤＥＬＬＩ　Ａｌｂｅｒｔｏ: 'Ａｌｔｅｒａｚｉｏｎｉ　ｇｅｎｅｔｉｃｈｅ　ｅ　ａｎａｌｉｓｉ　ｆｕｎｚｉｏｎａｌｅ　ｄｅｌｌａ　ｐｒｏｔｅｉｎａ　ｃｈｉｎａｓｉ　ＭＬＫ４　ｎｅｉ　ｔｕｍｏｒｉ　ｕｍａｎｉ' ＯＳＩＲＩＳ　-　Ｃｅｎｔｒｏ　ｄｉ　Ｄｏｃｕｍｅｎｔａｚｉｏｎｅ　ｅ　Ｃｏｎｄｉｖｉｓｉｏｎｅ　ｄｅｌｌｅ　Ｃｏｎｏｓｃｅｎｚｅ , 20091012, ＯＳＩＲＩＳ *
JPN6014042803; Ｓｃｉｅｎｃｅ Ｖｏｌ．３００, 2003, ｐ．９４９ *
JPN6014042805; Ｄｉｇｅｓｔｉｖｅ　ａｎｄ　Ｌｉｖｅｒ　Ｄｉｓｅａｓｅ Ｖｏｌ．３８, 2006, ｐ．２８３-２８６ *

Also Published As

Publication number Publication date
EP2582837A1 (en) 2013-04-24
US20130136755A1 (en) 2013-05-30
CA2804335A1 (en) 2011-12-22
AU2010355523A1 (en) 2013-01-10
WO2011158061A1 (en) 2011-12-22
AU2010355523B2 (en) 2014-09-11
US9127319B2 (en) 2015-09-08

Similar Documents

Publication Publication Date Title
Tu et al. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma
Zhou et al. Mutant KRAS-activated circATXN7 fosters tumor immunoescape by sensitizing tumor-specific T cells to activation-induced cell death
Li et al. ENO1 promotes lung cancer metastasis via HGFR and WNT signaling–driven epithelial-to-mesenchymal transition
Liao et al. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer
Yamamoto et al. Established gastric cancer cell lines transplantable into C57 BL/6 mice show fibroblast growth factor receptor 4 promotion of tumor growth
Agaram et al. Molecular characterization of pediatric gastrointestinal stromal tumors
Liu et al. Mutant SF3B1 promotes AKT-and NF-κB–driven mammary tumorigenesis
Barbieri et al. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten
Ruiz et al. JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancer
Costa et al. PAK4 suppresses RELB to prevent senescence-like growth arrest in breast cancer
Tang et al. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis
Ndiaye et al. VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness
Xu et al. NSCLC driven by DDR2 mutation is sensitive to dasatinib and JQ1 combination therapy
Sheu et al. Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells
Liu et al. Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma
Lee et al. Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma
Sung et al. Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation
AU2016252877A1 (en) Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (EGFR) with a combination of three fully human monoclonal anti-EGFR antibodies
WO2011123427A2 (en) Treatment of cancer by inhibiting activity or expression of late sv-40 factor
Hughes et al. Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion
Grasso et al. The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries
Finegan et al. The mitogen-activated protein kinase kinase 4 has a pro-oncogenic role in skin cancer
Ozkaya et al. Identification and targeting of kinase alterations in histiocytic neoplasms
Lee et al. Prevalence of mutations in discoidin domain-containing receptor tyrosine kinase 2 (DDR2) in squamous cell lung cancers in Korean patients
Kondo et al. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150608